Windlas Biotech Limited — Board Meeting, 12-08-2025: Outcome of Board Meeting

Windlas Biotech's board has approved the financial results for the quarter ended June 30, 2025. The company reported robust consolidated performance, with Revenue from Operations jumping to ₹210.09 Cr from ₹175.15 Cr in the same quarter last year. Profit for the quarter also saw a healthy rise, reaching ₹17.66 Cr compared to ₹13.48 Cr previously. This translates to a Basic EPS of ₹8.43, up from ₹6.47, reflecting strong growth and operational efficiency.